Fast Track is intended to expedite the development and review of therapies aimed at serious conditions with unmet medical needs. According to FDA policy, ISM6331’s designation reflects the agency’s recognition of potential clinical value, potentially enabling more intensive engagement during trial planning and biomarker strategy development.

The company positions ISM6331 as a candidate with “best-in-class” potential, engineered to rebalance the Hippo signaling pathway by targeting TEAD transcription factors. By restoring pathway balance, the program aims to suppress tumor growth and survival mechanisms associated with Hippo pathway dysregulation. The rationale is designed to support both monotherapy activity and combination strategies where resistance often limits efficacy.

ISM6331 was nominated in June 2023, with the molecular scaffold generated through Insilico’s Chemistry42 platform. Chemistry42 applies structure-based drug design and uses advanced scoring and reward pipelines to prioritize novel molecules, integrating generative chemistry techniques into the discovery workflow. This AI-driven design-to-prioritization framework underpins the candidate’s development pathway.

Insilico reports that ISM6331’s non-covalent structure is guided by Chemistry42, and preclinical studies suggest broad anti-tumor activity, potent effects at low doses, and a favorable safety profile with acceptable ADMET characteristics. The company also emphasizes synergistic anti-tumor effects and the potential to overcome drug resistance when used in combination therapy.

Previously, ISM6331 received FDA Orphan Drug Designation for mesothelioma in June 2024. Earlier designations related to other Insilico programs—such as Rentosertib (ISM001-055)—highlight the company’s growing regulatory footprint across oncology and beyond.

The Phase I first-in-human program for ISM6331 has advanced to the point where initial clinical data have been accepted for presentation in a brief oral format at the upcoming ESMO 2026 congress. In January 2025, Insilico states that the first patient was dosed in a global multicenter Phase I trial.

With Fast Track Designation, ISM6331 may be eligible—if criteria are met—for Rolling Review, Accelerated Approval, and Priority Review. Rolling Review could allow the submission of completed portions of an NDA or BLA to the FDA as they become available, potentially shortening time to regulatory consideration.

Overall, the company frames the FDA decision as validation of ISM6331’s clinical promise and as a pathway to accelerate development toward patients who need new treatment options in advanced mesothelioma.

Subject of Research: Pan-TEAD inhibition in malignant pleural mesothelioma; Hippo pathway modulation
Article Title: Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma
News Publication Date: July 29, 2026
Web References: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track ; https://www.prnewswire.com/news-releases/insilico-medicine-announces-oral-presentation-at-esmo-2026-for-phase-1-clinical-study-of-ism6331-in-mesothelioma-and-advanced-solid-tumors-302835019.html ; https://sciencesources.eurekalert.org/news-releases/1053820
References: Orphan Drug Designation context for ISM6331 (June 2024) and prior Insilico regulatory updates described in the release
Image Credits: Insilico Medicine
Keywords: Fast Track Designation, ISM6331, pan-TEAD inhibitor, Hippo pathway, malignant pleural mesothelioma, FDA, Chemistry42, generative AI, oncology clinical development

The innovative therapeutic approach combines alnodesertib, a targeted ATR inhibitor, with a low dose of irinotecan, a chemotherapy agent known to induce DNA damage. By exploiting the vulnerability of cancer cells lacking ATM—an essential protein responsible for detecting and initiating repair of DNA double-strand breaks—the combination therapy effectively disrupts cancer cell survival. While irinotecan damages the cancer cell DNA, alnodesertib blocks the ATR protein’s activity, preventing the cell’s ability to mend the induced damage, ultimately leading to cancer cell death.

Susanna Ulahannan, M.D., an oncologist at the University of Oklahoma and the national principal investigator for the colorectal cancer cohort in the STELLA trial, describes the treatment as a “triple hit.” This characterization reflects the targeted nature of the intervention directed specifically at ATM-deficient tumors, and the synergistic action of two agents: one that induces lethal DNA damage and the other that disables the cellular repair machinery.

The scientific rationale behind this combination lies in the interdependent roles of ATM and ATR proteins within the DNA damage response (DDR) pathway. ATM primarily responds to DNA double-strand breaks by activating repair pathways and cell-cycle checkpoints. Tumors deficient in ATM are inherently compromised in their ability to detect and resolve DNA damage. Consequently, inhibiting ATR in these cells with alnodesertib exacerbates genomic instability, tipping cancer cells toward apoptosis. This approach selectively targets malignant cells while sparing normal cells with intact DNA repair systems, potentially minimizing systemic toxicity.

Clinical outcomes from the trial have been encouraging. A significant portion of patients presenting ATM-deficient tumors exhibited measurable tumor shrinkage following treatment, an achievement noteworthy given the limited options available for metastatic colorectal cancer after multiple lines of prior therapy. These results underscore the potential of precision medicine strategies that tailor treatment based on tumor genetics and biology.

The combination’s Fast Track Designation emphasizes the urgent need for effective therapies in metastatic colorectal cancer, particularly as current options have been limited and disease prognosis remains poor. Colorectal cancer remains a leading cause of cancer-related deaths worldwide, with projections estimating over 154,000 new diagnoses and approximately 52,000 deaths in 2025 alone in the United States. Furthermore, the rising incidence of colorectal cancer in younger populations under 50 years old adds urgency to the development of novel interventions.

Mechanistically, irinotecan exerts antitumor effects by inhibiting topoisomerase I, an enzyme that alleviates DNA supercoiling during replication. Its inhibition leads to DNA breaks that, if unrepaired, cause replication fork collapse and cell death. In tandem, alnodesertib’s inhibition of ATR prevents the activation of cell cycle checkpoints and DDR pathways essential to the survival of cancer cells facing replication stress.

This clinical innovation showcases the growing trend of exploiting synthetic lethality in oncology. By identifying genetic or functional weaknesses in cancer cells—such as ATM deficiency—and targeting compensatory pathways like ATR, researchers can induce selective tumor cell death. Such strategies represent a paradigm shift from traditional cytotoxic therapies toward precision-targeted treatments with potentially improved efficacy and reduced toxicity.

The STELLA trial’s design incorporated patients who had undergone at least two prior colorectal cancer treatments without achieving durable responses. The marked tumor responses observed in this heavily pretreated cohort highlight the combination’s therapeutic promise even in resistant disease settings. Ongoing research will further clarify optimal patient selection, dosing strategies, and long-term outcomes associated with this approach.

In summary, the therapeutic synergy between alnodesertib and irinotecan embodies a novel and rational strategy that targets the DNA repair vulnerabilities of metastatic colorectal cancer. The positive clinical trial data have secured FDA Fast Track Designation, expediting the pathway toward broader clinical application. As research continues, this approach may redefine the standard of care for a patient population with historically limited options, offering renewed hope for improved survival and quality of life.

Subject of Research: People
Article Title: Not provided
News Publication Date: Not provided
Web References: https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html
References: Not provided
Image Credits: University of Oklahoma
Keywords: Colorectal cancer, Chemotherapy, Cancer treatments, Combination therapies, DNA repair genes